Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Smitha, Zaharoff"'
Autor:
Nicholas A. Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki, Thomas Lodise, Varduhi Ghazaryan, Tatiana Beresnev, Todd Riccobene, Rinal Patel, Sarah B. Doernberg, Urania Rappo, Vance G. Fowler, Thomas L. Holland, on behalf of the Antibacterial Resistance Leadership Group (ARLG)
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-15 (2022)
Abstract Background Staphylococcus aureus bacteremia is a life-threatening infection and leading cause of infective endocarditis, with mortality rates of 15–50%. Treatment typically requires prolonged administration of parenteral therapy, itself as
Externí odkaz:
https://doaj.org/article/a09ef7c8d4244ac5b80e26defc820dae
Autor:
Thomas P, Lodise, J Nicholas, O'Donnell, Shruti, Raja, Jeffrey T, Guptill, Smitha, Zaharoff, Nyssa, Schwager, Vance G, Fowler, Tatiana, Beresnev, Alison, Wall, Katherine, Wiegand, Elisavet, Serti Chrisos, Stephen, Balevic, Henry F, Chambers
Publikováno v:
Antimicrob Agents Chemother
This phase I study evaluated the safety of the optimal ceftazidime-avibactam (CZA) with aztreonam (ATM) regimens identified in hollow fiber infection models of MBL-producing Enterobacterales. Eligible healthy subjects aged 18 to 45 years were assigne
Autor:
Thomas Lodise, J Nicholas O’Donnell, Shruti Raja, Stephen Balevic, Jeffrey Guptill, Nyssa Schwager, Smitha Zaharoff, Vance G Fowler, Varduhi Ghazaryan, Tatiana Beresnev, Alison wall, Katherine Wiegand, Henry Chambers
Publikováno v:
Open Forum Infectious Diseases. 9
Background The combination of CZA-ATM is frequently used to treat patients with metallo-β-lactamase (MBL)-producing Enterobacterales (EB) infections, but its safety has not been established in controlled trials. This phase 1 study evaluated the safe
Autor:
Thomas Lodise, J Nicholas O’Donnell, Stephen Balevic, Xing Liu, Kenan Gu, Jomy George, Shruti Raja, Jeffrey Guptill, Smitha Zaharoff, Nyssa Schwager, Vance G Fowler, Henry Chambers
Publikováno v:
Open Forum Infectious Diseases. 9
Background Scant PK data are available with CZA-ATM in combination. Occurrence of ALT/AST elevations are common with ATM, and it is unknown if it is exacerbated by use of CZA-ATM. This analysis of COMBINE sought to describe the popPK of CZA-ATM and t
Publikováno v:
J Antimicrob Chemother
Objectives Dalbavancin is a lipoglycopeptide with a long half-life, making it a promising treatment for infections requiring prolonged therapy, such as complicated Staphylococcus aureus bacteraemia. Free drug concentration is a critical consideration
Publikováno v:
Open Forum Infectious Diseases. 8:S638-S638
Background Dalbavancin is a semi-synthetic glycopeptide with a long half-life, making it a promising alternative for infections requiring prolonged therapy such as complicated Staphylococcus aureus bacteremia. A critical pharmacokinetic consideration
Publikováno v:
Open Forum Infectious Diseases. 2022 Supplement, Vol. 9, pS1-S936. 2220p.
Autor:
Turner, Nicholas A.1 (AUTHOR), Zaharoff, Smitha2 (AUTHOR), King, Heather3,4 (AUTHOR), Evans, Scott5 (AUTHOR), Hamasaki, Toshimitsu5 (AUTHOR), Lodise, Thomas6 (AUTHOR), Ghazaryan, Varduhi7 (AUTHOR), Beresnev, Tatiana7 (AUTHOR), Riccobene, Todd8 (AUTHOR), Patel, Rinal8 (AUTHOR), Doernberg, Sarah B.9 (AUTHOR), Rappo, Urania10 (AUTHOR), Fowler Jr, Vance G.1 (AUTHOR), Holland, Thomas L.1 (AUTHOR) thomas.holland@duke.edu, Fowler, Vance G Jr1 (AUTHOR), Antibacterial Resistance Leadership Group (ARLG) (CORPORATE AUTHOR)
Publikováno v:
Trials. 5/16/2022, Vol. 23 Issue 1, p1-15. 15p. 1 Diagram, 2 Charts.
Publikováno v:
Journal of Antimicrobial Chemotherapy (JAC); Jul2022, Vol. 77 Issue 7, p1899-1902, 4p
Publikováno v:
Clinical Trials Week; 10/30/2023, p1963-1963, 1p